



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

November 2016





HIV/AIDS Drug Treatment Program

Monthly Report

© 2017 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

November 2016

N = 7174



Health Authority	Male	Female	All
FRASER	1358	387	1745
INTERIOR	375	98	473
NORTHERN	138	78	216
VANCOUVER COASTAL	3394	452	3846
VANCOUVER ISLAND	703	160	863
	5968	1175	7143
		Unknown/not stated:	31
		Total:	7174

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2011 - November 2016)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2011 - November 2016)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (November 2011 - November 2016)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (November 2011 - November 2016)






1.6 Percent Distribution of Active Participants by CD4 Count
(November 2011 - November 2016)






1.7 Percent Distribution of Inactive Participants by CD4 Count (November 2011 - November 2016)






1.8 Active and Inactive Participants (November 2011 - November 2016)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (November 2011 - November 2016)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (November 2011 - November 2016)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(November 2011 - November 2016)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (November 2011 - November 2016)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT (November 2011 - November 2016)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (November 2011 - November 2016)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(November 2011 - November 2016)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (November 2011 - November 2016)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(November 2011 - November 2016)






1.18 Baseline CD4 for Antiretroviral First Starts (November 2011 - November 2016)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(November 2011 - November 2016)**






1.20 Cumulative Resistance Testing Results by Resistance Category (November 2011 - November 2016)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (November 2011 - November 2016)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2016
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	5	0	5	4	810	5	<40	3
1988	24	7	0	7	7	550	7	<40	3
1989	24	55	2	57	50	530	56	<40	3
1990	22	61	1	62	59	550	62	<40	3
1991	22	37	3	40	30	605	38	<40	3
1992	22	68	7	75	60	600	72	<40	3
1993	21	144	16	160	145	560	157	<40	3
1994	20	93	13	106	91	570	102	<40	3
1995	20	126	24	150	127	560	145	<40	3
1996	18	369	61	430	377	600	415	<40	3
1997	16	301	39	340	299	640	321	<40	3
1998	15	217	42	259	219	560	242	<40	3
1999	15	179	42	221	197	570	210	<40	3
2000	15	140	36	176	152	575	171	<40	3
2001	15	132	34	166	146	571	157	<40	3
2002	14	140	28	168	147	540	165	<40	3
2003	13	173	32	205	185	590	199	<40	3
2004	12	176	42	218	187	610	206	<40	3
2005	11	204	48	252	214	610	237	<40	3
2006	10	211	49	260	214	565	245	<40	3
2007	9	277	55	332	284	620	312	<40	3
2008	8	310	69	379	317	620	358	<40	3
2009	7	339	77	416	355	630	401	<40	3
2010	6	308	71	379	322	610	354	<40	3
2011	5	365	78	443	382	650	418	<40	3
2012	4	299	63	362	308	670	344	<40	3
2013	3	286	70	356	303	630	341	<40	3
2014	2	311	58	369	308	700	351	<40	3
2015	1	336	57	393	334	631	374	<40	3
2016	0	305	60	365	337	550	354	<40	3
Total:		5974	1177	7151					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	6739	760	2430	<40	2189	580
FEB-2015	6787	754	1975	<40	1778	580
MAR-2015	6834	748	2173	<40	1973	570
APR-2015	6845	739	2150	<40	1971	580
MAY-2015	6881	740	2032	<40	1842	560
JUN-2015	6897	740	2254	<40	2044	580
JUL-2015	6924	739	2037	<40	1854	580
AUG-2015	6922	752	2074	<40	1830	580
SEP-2015	6922	749	2265	<40	2059	580
OCT-2015	6957	740	2100	<40	1878	590
NOV-2015	7008	722	2064	<40	1875	580
DEC-2015	6988	725	2015	<40	1830	600
JAN-2016	6974	737	2264	<40	2021	590
FEB-2016	6993	735	2067	<40	1866	590
MAR-2016	6998	737	2155	<40	1956	590
APR-2016	7017	734	2053	<40	1863	580
MAY-2016	7045	747	2072	<40	1881	590
JUN-2016	7065	739	2180	<40	1988	610
JUL-2016	7057	752	1949	<40	1755	600
AUG-2016	7071	751	2066	<40	1850	600
SEP-2016	7113	752	2217	<40	1971	600
OCT-2016	7145	747	2157	<40	1879	610
NOV-2016	7174	743	2111	<40	1799	590

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	1513	2042	104	1325	88	330
FEB-2015	1497	2111	103	75	89	380
MAR-2015	1469	2260	101	56	95	410
APR-2015	1475	2244	83	2239	73	460
MAY-2015	1460	2339	73	148	65	380
JUN-2015	1477	2263	96	106	92	420
JUL-2015	1470	2326	71	598	60	380
AUG-2015	1480	2303	82	2341	77	440
SEP-2015	1504	2231	91	128	86	370
OCT-2015	1486	2347	81	<40	70	405
NOV-2015	1463	2458	85	169	78	400
DEC-2015	1500	2312	79	344	64	330
JAN-2016	1512	2286	114	<40	102	470
FEB-2016	1504	2348	80	751	71	380
MAR-2016	1512	2315	87	130	83	440
APR-2016	1516	2310	87	<50	73	360
MAY-2016	1502	2388	78	<40	68	350
JUN-2016	1512	2380	71	65	55	510
JUL-2016	1535	2334	81	57	75	450
AUG-2016	1562	2225	96	118	80	370
SEP-2016	1546	2300	93	231	77	400
OCT-2016	1519	2470	70	56	66	465
NOV-2016	1522	2490	72	631	56	380

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2015	6706	1513	13	24	149	188	-35	11954
FEB-2015	6756	1497	7	36	187	163	50	12006
MAR-2015	6809	1469	7	29	177	144	53	12046
APR-2015	6808	1475	15	28	168	172	-1	12082
MAY-2015	6846	1460	9	33	170	150	38	12123
JUN-2015	6869	1477	5	36	153	159	23	12170
JUL-2015	6905	1470	5	25	167	149	36	12208
AUG-2015	6903	1480	7	19	145	156	-2	12238
SEP-2015	6898	1504	9	32	157	180	-5	12279
OCT-2015	6926	1486	14	24	171	147	28	12316
NOV-2015	6977	1463	9	29	183	150	51	12357
DEC-2015	6954	1500	11	21	153	182	-23	12389
JAN-2016	6944	1512	9	16	154	168	-10	12410
FEB-2016	6964	1504	5	18	177	162	20	12438
MAR-2016	6971	1512	9	24	168	172	7	12472
APR-2016	6991	1516	6	20	166	157	20	12506
MAY-2016	7020	1502	7	23	159	144	29	12537
JUN-2016	7035	1512	12	34	162	165	15	12580
JUL-2016	7020	1535	10	25	134	154	-15	12612
AUG-2016	7035	1562	10	40	164	174	15	12672
SEP-2016	7083	1546	5	27	182	149	48	12715
OCT-2016	7115	1519	11	22	161	137	32	12746
NOV-2016	7151	1522	8	29	178	163	36	12793

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2015	48	6180	440	74	6742	0.71%	91.66%	6.53%	1.10%	100.00%
FEB-2015	49	6219	451	73	6792	0.72%	91.56%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	47	6296	435	67	6845	0.69%	91.98%	6.36%	0.98%	100.00%
MAY-2015	49	6334	431	68	6882	0.71%	92.04%	6.26%	0.99%	100.00%
JUN-2015	51	6329	446	72	6898	0.74%	91.75%	6.47%	1.04%	100.00%
JUL-2015	46	6359	453	67	6925	0.66%	91.83%	6.54%	0.97%	100.00%
AUG-2015	49	6359	444	70	6922	0.71%	91.87%	6.41%	1.01%	100.00%
SEP-2015	49	6370	439	64	6922	0.71%	92.03%	6.34%	0.92%	100.00%
OCT-2015	52	6399	442	64	6957	0.75%	91.98%	6.35%	0.92%	100.00%
NOV-2015	57	6439	445	67	7008	0.81%	91.88%	6.35%	0.96%	100.00%
DEC-2015	53	6425	448	62	6988	0.76%	91.94%	6.41%	0.89%	100.00%
JAN-2016	55	6410	448	61	6974	0.79%	91.91%	6.42%	0.87%	100.00%
FEB-2016	58	6439	437	59	6993	0.83%	92.08%	6.25%	0.84%	100.00%
MAR-2016	54	6445	438	61	6998	0.77%	92.10%	6.26%	0.87%	100.00%
APR-2016	54	6464	442	57	7017	0.77%	92.12%	6.30%	0.81%	100.00%
MAY-2016	57	6495	439	54	7045	0.81%	92.19%	6.23%	0.77%	100.00%
JUN-2016	60	6502	447	56	7065	0.85%	92.03%	6.33%	0.79%	100.00%
JUL-2016	57	6501	442	57	7057	0.81%	92.12%	6.26%	0.81%	100.00%
AUG-2016	57	6511	447	56	7071	0.81%	92.08%	6.32%	0.79%	100.00%
SEP-2016	58	6550	448	57	7113	0.82%	92.08%	6.30%	0.80%	100.00%
OCT-2016	58	6584	446	57	7145	0.81%	92.15%	6.24%	0.80%	100.00%
NOV-2016	59	6609	447	59	7174	0.82%	92.12%	6.23%	0.82%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		emtricitabine		tenofovir <TAF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	10 29%	2583 40%	10 29%	2220 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3846 59%	0 0%	0 0%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3878 59%	0 0%	0 0%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3913 59%	0 0%	0 0%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3911 59%	0 0%	0 0%
MAY-2015	8 20%	2638 40%	7 18%	2280 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3922 59%	0 0%	0 0%
JUN-2015	10 21%	2633 39%	10 21%	2287 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3941 59%	0 0%	0 0%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3944 59%	0 0%	0 0%
AUG-2015	12 40%	2675 40%	11 37%	2334 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3941 59%	0 0%	0 0%
SEP-2015	17 41%	2715 40%	15 37%	2373 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	24 59%	3911 58%	0 0%	0 0%
OCT-2015	11 30%	2747 41%	10 27%	2404 36%	0 0%	102 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3901 58%	0 0%	0 0%
NOV-2015	17 41%	2785 41%	15 37%	2440 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3910 58%	0 0%	0 0%
DEC-2015	5 16%	2793 41%	5 16%	2454 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	27 84%	3883 57%	0 0%	0 0%
JAN-2016	4 19%	2819 42%	4 19%	2486 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	17 81%	3852 57%	0 0%	0 0%
FEB-2016	10 36%	2854 42%	9 32%	2522 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	18 64%	3830 57%	0 0%	0 0%
MAR-2016	9 26%	2878 43%	7 21%	2543 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	25 74%	3811 56%	0 0%	0 0%
APR-2016	12 35%	2893 43%	9 26%	2567 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	22 65%	3815 56%	0 0%	5 0%
MAY-2016	8 26%	2894 43%	8 26%	2578 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	23 74%	3836 56%	0 0%	6 0%
JUN-2016	11 26%	2924 43%	11 26%	2602 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	32 74%	3832 56%	1 2%	9 0%
JUL-2016	9 28%	2903 43%	9 28%	2583 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	23 72%	3835 56%	0 0%	9 0%
AUG-2016	11 19%	2936 43%	11 19%	2627 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	48 81%	3833 56%	6 10%	22 0%
SEP-2016	14 33%	2970 43%	12 28%	2661 39%	0 0%	81 1%	0 0%	8 0%	0 0%	6 0%	29 67%	3850 56%	3 7%	25 0%
OCT-2016	11 35%	2998 43%	11 35%	2691 39%	0 0%	82 1%	0 0%	9 0%	0 0%	7 0%	20 65%	3854 56%	0 0%	26 0%
NOV-2016	17 36%	3027 44%	17 36%	2726 39%	0 0%	78 1%	0 0%	7 0%	0 0%	6 0%	30 64%	3857 56%	0 0%	35 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	tenofovir <TDF>			
	Initial		All	
JAN-2015	25	71%	4210	64%
FEB-2015	44	85%	4241	64%
MAR-2015	30	75%	4269	64%
APR-2015	24	69%	4267	64%
MAY-2015	33	83%	4276	64%
JUN-2015	37	79%	4292	64%
JUL-2015	34	89%	4294	64%
AUG-2015	18	60%	4281	64%
SEP-2015	24	59%	4251	63%
OCT-2015	27	73%	4239	63%
NOV-2015	25	61%	4242	63%
DEC-2015	27	84%	4208	62%
JAN-2016	17	81%	4169	62%
FEB-2016	18	64%	4137	61%
MAR-2016	26	76%	4114	61%
APR-2016	22	65%	4107	61%
MAY-2016	23	74%	4122	61%
JUN-2016	31	72%	4120	60%
JUL-2016	23	72%	4118	60%
AUG-2016	42	71%	4099	60%
SEP-2016	27	63%	4106	60%
OCT-2016	20	65%	4105	59%
NOV-2016	30	64%	4093	59%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	0 0%	12 0%	6 50%	2029 60%	6 50%	930 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2029 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	970 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 1%
APR-2015	0 0%	12 0%	7 33%	2025 60%	14 67%	988 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	1999 59%	6 38%	1018 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1965 58%	10 56%	1037 31%	0 0%	358 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1957 58%	11 79%	1050 31%	1 7%	351 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1946 58%	7 64%	1054 31%	3 27%	345 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1912 58%	11 69%	1060 32%	1 6%	338 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1900 57%	10 63%	1087 33%	1 6%	331 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	4 27%	1875 56%	9 60%	1107 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
DEC-2015	0 0%	11 0%	3 25%	1838 56%	8 67%	1118 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1130 34%	1 9%	327 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1157 35%	1 8%	318 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1171 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1198 37%	0 0%	294 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1728 53%	10 83%	1221 38%	0 0%	283 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1709 53%	12 80%	1237 38%	0 0%	284 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	3 21%	1690 53%	11 79%	1243 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1664 52%	26 90%	1255 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1644 52%	9 82%	1272 40%	1 9%	262 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%
OCT-2016	0 0%	8 0%	2 18%	1617 51%	9 82%	1267 40%	0 0%	261 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
NOV-2016	0 0%	9 0%	4 20%	1592 51%	15 75%	1281 41%	1 5%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%
DEC-2015	0	0%	1	0%
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%
OCT-2016	0	0%	1	0%
NOV-2016	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	253 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	250 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%
OCT-2015	2 50%	1083 43%	0 0%	312 12%	1 25%	867 35%	1 25%	251 10%
NOV-2015	4 67%	1074 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%
DEC-2015	2 100%	1055 42%	0 0%	312 13%	0 0%	863 35%	0 0%	254 10%
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	997 41%	0 0%	307 13%	1 25%	854 35%	1 25%	258 11%
APR-2016	3 33%	991 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	970 41%	1 25%	299 13%	2 50%	837 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	296 13%	0 0%	831 35%	2 29%	261 11%
SEP-2016	2 50%	951 41%	0 0%	295 13%	0 0%	820 35%	2 50%	264 11%
OCT-2016	1 20%	946 41%	2 40%	300 13%	1 20%	815 35%	1 20%	268 12%
NOV-2016	7 78%	935 40%	1 11%	294 13%	0 0%	811 35%	1 11%	270 12%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	13 72%	540 30%	4 22%	348 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	575 31%	8 33%	354 19%	0 0%	73 4%	2 8%	879 48%	0 0%	1 0%
MAR-2015	9 50%	599 32%	5 28%	367 20%	0 0%	69 4%	4 22%	868 47%	0 0%	2 0%
APR-2015	7 50%	627 33%	4 29%	373 20%	2 14%	67 4%	1 7%	861 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	380 20%	1 6%	70 4%	2 12%	863 44%	0 0%	2 0%
JUN-2015	15 56%	710 35%	8 30%	394 20%	0 0%	72 4%	4 15%	875 44%	0 0%	1 0%
JUL-2015	11 58%	746 36%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	11 69%	781 38%	4 25%	413 20%	0 0%	70 3%	1 6%	854 41%	0 0%	1 0%
SEP-2015	17 85%	847 40%	1 5%	412 19%	0 0%	65 3%	2 10%	855 40%	0 0%	1 0%
OCT-2015	14 70%	889 40%	6 30%	435 20%	0 0%	65 3%	0 0%	851 39%	0 0%	1 0%
NOV-2015	15 71%	938 42%	6 29%	438 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%
DEC-2015	11 50%	988 43%	10 45%	445 19%	0 0%	66 3%	1 5%	841 37%	0 0%	1 0%
JAN-2016	6 55%	1021 44%	4 36%	461 20%	0 0%	67 3%	1 9%	822 35%	0 0%	1 0%
FEB-2016	7 64%	1063 45%	4 36%	469 20%	0 0%	61 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1116 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1154 47%	4 22%	492 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1183 47%	4 24%	494 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1216 48%	9 35%	506 20%	0 0%	58 2%	1 4%	788 31%	0 0%	1 0%
JUL-2016	14 70%	1251 49%	5 25%	518 20%	0 0%	57 2%	1 5%	784 30%	0 0%	1 0%
AUG-2016	20 59%	1304 49%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1364 50%	10 33%	545 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%
OCT-2016	15 94%	1413 51%	1 6%	561 20%	0 0%	53 2%	0 0%	777 28%	0 0%	1 0%
NOV-2016	18 72%	1456 52%	5 20%	582 21%	0 0%	53 2%	2 8%	756 27%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2015	2347	34.81	2123	31.49	1137	16.86	179	2.65	74	1.10	882	13.08
FEB-2015	2363	34.79	2110	31.07	1176	17.31	178	2.62	73	1.07	892	13.13
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2388	34.89	2095	30.61	1237	18.07	184	2.69	67	0.98	874	12.77
MAY-2015	2392	34.76	2094	30.43	1274	18.51	179	2.60	68	0.99	875	12.71
JUN-2015	2363	34.26	2078	30.12	1321	19.15	172	2.49	72	1.04	892	12.93
JUL-2015	2370	34.22	2068	29.86	1352	19.52	171	2.47	67	0.97	897	12.95
AUG-2015	2365	34.17	2044	29.53	1381	19.95	168	2.43	70	1.01	894	12.92
SEP-2015	2323	33.56	2032	29.36	1444	20.86	168	2.43	64	0.92	891	12.87
OCT-2015	2325	33.42	2005	28.82	1491	21.43	167	2.40	64	0.92	905	13.01
NOV-2015	2315	33.03	2012	28.71	1540	21.97	160	2.28	67	0.96	914	13.04
DEC-2015	2288	32.74	1982	28.36	1580	22.61	161	2.30	62	0.89	915	13.09
JAN-2016	2286	32.78	1944	27.87	1612	23.11	158	2.27	61	0.87	913	13.09
FEB-2016	2280	32.60	1925	27.53	1669	23.87	153	2.19	59	0.84	907	12.97
MAR-2016	2266	32.38	1905	27.22	1707	24.39	154	2.20	61	0.87	905	12.93
APR-2016	2244	31.98	1895	27.01	1756	25.02	154	2.19	57	0.81	911	12.98
MAY-2016	2256	32.02	1887	26.78	1781	25.28	157	2.23	54	0.77	910	12.92
JUN-2016	2258	31.96	1877	26.57	1811	25.63	152	2.15	56	0.79	911	12.89
JUL-2016	2227	31.56	1867	26.46	1848	26.19	150	2.13	57	0.81	908	12.87
AUG-2016	2212	31.28	1840	26.02	1913	27.05	142	2.01	56	0.79	908	12.84
SEP-2016	2194	30.84	1833	25.77	1977	27.79	144	2.02	57	0.80	908	12.77
OCT-2016	2173	30.41	1830	25.61	2035	28.48	146	2.04	57	0.80	904	12.65
NOV-2016	2176	30.33	1817	25.33	2078	28.97	143	1.99	59	0.82	901	12.56

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	19	2	3	4	2	7	400
SEP-2015	32	7	1	5	2	15	505
OCT-2015	24	4	2	3	4	9	450
NOV-2015	29	5	1	6	5	10	370
DEC-2015	21	1	3	4	5	7	375
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	24	4	3	4	8	5	365
APR-2016	20	2	1	2	2	9	580
MAY-2016	23	2	1	3	4	13	510
JUN-2016	34	5	5	6	10	8	380
JUL-2016	25	2	6	6	3	7	320
AUG-2016	40	2	7	6	12	13	410
SEP-2016	27	8	2	6	4	4	253
OCT-2016	22	2	2	6	6	5	370
NOV-2016	29	3	4	5	8	9	420

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2015	10389	2657
FEB-2015	10435	2664
MAR-2015	10474	2673
APR-2015	10494	2685
MAY-2015	10548	2709
JUN-2015	10635	2757
JUL-2015	10704	2805
AUG-2015	10770	2861
SEP-2015	10855	2916
OCT-2015	10907	2956
NOV-2015	10970	2996
DEC-2015	11016	3024
JAN-2016	11050	3054
FEB-2016	11143	3135
MAR-2016	11203	3183
APR-2016	11249	3216
MAY-2016	11309	3265
JUN-2016	11365	3296
JUL-2016	11409	3331
AUG-2016	11454	3337
SEP-2016	11481	3341
OCT-2016	11513	3366
NOV-2016	11571	3389

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
November 2016

N = 7174

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2016

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2016

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2016

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2016

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2016

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	33	46	21
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	72	94	54	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	335	440	260	
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	20	20	15
	35-49	56	64	41
	50+	97	146	82
Total HSDA:	178	235	138	
Total HA:		618	815	473

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	55	56	*
	35-49	175	203	*
	50+	379	547	*
Total HA:		618	815	473

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	483	649	375
Female	135	166	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	473	53	580	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	17	*
	5 years or more	5	*
	<5 years	11	*
	Total HSDA:	33	21
KOOTENAY BOUNDARY	10 years or more	38	27
	5 years or more	18	14
	<5 years	16	13
	Total HSDA:	72	54
OKANAGAN	10 years or more	178	127
	5 years or more	73	60
	<5 years	84	73
	Total HSDA:	335	260
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	90	62
	5 years or more	45	40
	<5 years	43	36
	Total HSDA:	178	138
Total HA:		618	473

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	323	226
	5 years or more	141	118
	<5 years	154	129
Total HA:		618	473

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	36	53	13	23
KOOTENAY BOUNDARY	63	112	23	40
OKANAGAN	195	686	61	249
THOMPSON/CARIBOO/SHUSWAP	126	428	35	107
Total:	420	1279	132	419

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	100

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	25	26	18
	35-49	107	119	74
	50+	182	246	147
	Total HSDA:	320	397	244
FRASER NORTH	0-19	18	18	5
	20-34	104	105	83
	35-49	356	402	267
	50+	489	758	401
	Total HSDA:	967	1283	756
FRASER SOUTH	0-19	10	10	6
	20-34	98	100	70
	35-49	361	415	297
	50+	446	654	372
	Total HSDA:	915	1179	745
Total HA:		2202	2859	1745

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	34	34	16
	20-34	227	231	171
	35-49	824	936	638
	50+	1117	1658	920
Total HA:		2202	2859	1745

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1674	2201	1358
Female	528	658	387

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1745	50	607	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	157	111
	5 years or more	90	75
	<5 years	73	58
	Total HSDA:	320	244
FRASER NORTH	10 years or more	472	347
	5 years or more	255	211
	<5 years	240	198
	Total HSDA:	967	756
FRASER SOUTH	10 years or more	426	333
	5 years or more	249	208
	<5 years	240	204
	Total HSDA:	915	745
Total HA:		2202	1745

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1055	791
	5 years or more	594	494
	<5 years	553	460
Total HA:		2202	1745

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	130	415	43	81
FRASER NORTH	233	1439	64	267
FRASER SOUTH	201	1202	43	338
Total:	564	3056	150	686

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	180
FRASER NORTH	629
FRASER SOUTH	507
Total:	1316

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	22
	35-49	*	*	68
	50+	*	*	191
	Total HSDA:		324	460
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		157	202
VANCOUVER	0-19	51	54	7
	20-34	423	432	327
	35-49	1533	1761	1135
	50+	2528	4207	1965
	Total HSDA:	4535	6454	3434
Total HA:		5016	7116	3846

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	57	60	8
	20-34	474	484	372
	35-49	1659	1905	1240
	50+	2826	4667	2226
Total HA:		5016	7116	3846

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4406	6251	3394
Female	608	863	452

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3846	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	171	144
	5 years or more	66	60
	<5 years	87	77
	Total HSDA:	324	281
RICHMOND	10 years or more	70	55
	5 years or more	39	32
	<5 years	48	44
	Total HSDA:	157	131
VANCOUVER	10 years or more	2338	1682
	5 years or more	1204	930
	<5 years	993	822
	Never on ART	0	0
	Total HSDA:	4535	3434
Total HA:	5016	3846	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2579	1881
5 years or more	1309	1022
<5 years	1128	943
Never on ART	0	0
Total HA:	5016	3846

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	146	377	58	101
RICHMOND	42	267	14	95
VANCOUVER	548	10058	212	5336
Total:	736	10702	284	5532

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	99

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		286	402
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		113	148
SOUTH VANCOUVER ISLAND	0-19	7	7	*
	20-34	53	55	*
	35-49	209	245	*
	50+	409	634	*
	Total HSDA:		678	941
Total HA:		1077	1491	863

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	5
	20-34	89	94	63
	35-49	334	383	267
	50+	643	1003	528
Total HA:		1077	1491	863

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	871	1208	703
Female	206	283	160

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	863	53	490	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	136	111
	5 years or more	64	53
	<5 years	86	72
	Total HSDA:	286	236
NORTH VANCOUVER ISLAND	10 years or more	53	44
	5 years or more	27	25
	<5 years	33	26
	Total HSDA:	113	95
SOUTH VANCOUVER ISLAND	10 years or more	349	247
	5 years or more	163	135
	<5 years	166	150
	Total HSDA:	678	532
Total HA:		1077	863

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	538	402
	5 years or more	254	213
	<5 years	285	248
Total HA:		1077	863

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	177	766	83	222
NORTH VANCOUVER ISLAND	122	243	45	71
SOUTH VANCOUVER ISLAND	188	1576	50	535
Total:	487	2585	178	828

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	43
NORTH VANCOUVER ISLAND	34
SOUTH VANCOUVER ISLAND	93
Total:	170

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		42	50
NORTH WEST	0-19	*	*	0
	20-34	*	*	5
	35-49	*	*	22
	50+	*	*	23
	Total HSDA:		68	101
NORTHERN INTERIOR	0-19	7	7	*
	20-34	25	27	*
	35-49	74	92	*
	50+	79	128	*
	Total HSDA:		185	254
Total HA:		295	405	216

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	37	44	*
	35-49	115	147	*
	50+	134	205	*
Total HA:		295	405	216

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	181	252	138
Female	114	153	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	216	48	540	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	14	5
	5 years or more	17	11
	<5 years	11	10
	Total HSDA:	42	26
NORTH WEST	10 years or more	17	8
	5 years or more	33	28
	<5 years	18	14
	Total HSDA:	68	50
NORTHERN INTERIOR	10 years or more	57	33
	5 years or more	55	47
	<5 years	73	60
	Total HSDA:	185	140
Total HA:		295	216

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	88	46
	5 years or more	105	86
	<5 years	102	84
Total HA:		295	216

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	33	59	9	11
NORTH WEST	66	146	21	29
NORTHERN INTERIOR	102	407	20	181
Total:	201	612	50	221

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	13
NORTHERN INTERIOR	17
Total:	36

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	29	*
	THOMPSON/CARIBOO/SHUSWAP	*	40	*
	Total HA:	49	86	37
FRASER	FRASER EAST	33	41	25
	FRASER NORTH	57	88	45
	FRASER SOUTH	74	103	59
	Total HA:	164	232	129
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	24	45	19
	RICHMOND	8	13	7
	VANCOUVER	506	796	417
	Total HA:	538	854	443
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	53	78	43
	NORTH VANCOUVER ISLAND	13	22	13
	SOUTH VANCOUVER ISLAND	36	73	30
	Total HA:	102	173	86
NORTHERN	NORTH EAST	9	11	6
	NORTH WEST	34	58	29
	NORTHERN INTERIOR	65	98	57
	Total HA:	108	167	92
Total:		961	1512	787

Total:

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	600	965	487
Female	361	547	300

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	787	49	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

